{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:08:13Z","timestamp":1790230093824,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-CA184274"],"award-info":[{"award-number":["R01-CA184274"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 DK058694"],"award-info":[{"award-number":["R01 DK058694"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA124723"],"award-info":[{"award-number":["R01 CA124723"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Robert and Katherine Goodale Foundation And Sit Family Foundation"}],"content-domain":{"domain":["pancreatology.net","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pancreatology"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.pan.2015.05.472","type":"journal-article","created":{"date-parts":[[2015,6,18]],"date-time":"2015-06-18T08:39:40Z","timestamp":1434616780000},"page":"S39-S43","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"special_numbering":"S","title":["Minnelide, a novel drug for pancreatic and liver cancer"],"prefix":"10.1016","volume":"15","author":[{"given":"Sulagna","family":"Banerjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok","family":"Saluja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.pan.2015.05.472_bib1","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3322\/caac.20073","article-title":"Cancer statistics, 2010","volume":"60","author":"Jemal","year":"2010","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.pan.2015.05.472_bib2","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.bpg.2005.10.001","article-title":"Epidemiology and risk factors for pancreatic cancer","volume":"20","author":"Lowenfels","year":"2006","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.pan.2015.05.472_bib3","first-page":"2007","article-title":"Pancreatic cancer","author":"O'Sullivan","year":"2007","journal-title":"Clin Evid"},{"issue":"9414","key":"10.1016\/j.pan.2015.05.472_bib4","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0140-6736(04)15841-8","article-title":"Pancreatic cancer","volume":"363","author":"Li","year":"2004","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.pan.2015.05.472_bib5","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3322\/canjclin.57.4.190","article-title":"Cancer incidence, mortality, and associated risk factors among Asian Americans of Chinese, Filipino, Vietnamese, Korean, and Japanese ethnicities","volume":"57","author":"McCracken","year":"2007","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"10.1016\/j.pan.2015.05.472_bib6","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1053\/j.gastro.2013.01.068","article-title":"The epidemiology of pancreatitis and pancreatic cancer","volume":"144","author":"Yadav","year":"2013","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.pan.2015.05.472_bib7","first-page":"44","article-title":"Current status of molecular markers for early detection of sporadic pancreatic cancer","volume":"1815","author":"Chakraborty","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.pan.2015.05.472_bib8","series-title":"Pancreatic cancer","author":"Binkley","year":"2004"},{"issue":"9822","key":"10.1016\/j.pan.2015.05.472_bib9","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0140-6736(11)61347-0","article-title":"Hepatocellular carcinoma","volume":"379","author":"Forner","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.pan.2015.05.472_bib10","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0140-6736(10)62307-0","article-title":"Pancreatic cancer","volume":"378","author":"Vincent","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.pan.2015.05.472_bib11","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nrgastro.2010.188","article-title":"Pancreatic cancer: understanding and overcoming chemoresistance","volume":"8","author":"Wang","year":"2011","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.pan.2015.05.472_bib12","unstructured":"Pancreatic Cancer Detailed Guide http:\/\/www.cancer.org\/cancer\/pancreaticcancer\/detailedguide\/index."},{"key":"10.1016\/j.pan.2015.05.472_bib13","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","article-title":"Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group","volume":"25","author":"Moore","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pan.2015.05.472_bib14","first-page":"391","article-title":"New developments in the treatment of pancreatic cancer. Highlights from the \u201c44th ASCO Annual Meeting\u201d. Chicago, IL, USA. May 30-June 3, 2008","volume":"9","author":"Saif","year":"2008","journal-title":"JOP"},{"key":"10.1016\/j.pan.2015.05.472_bib15","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1200\/JCO.2008.20.0238","article-title":"Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer","volume":"27","author":"Van Cutsem","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.pan.2015.05.472_bib16","doi-asserted-by":"crossref","first-page":"S136","DOI":"10.1016\/S0168-8278(02)00432-4","article-title":"Hepatocellular carcinoma: present status and future prospects","volume":"38","author":"Llovet","year":"2003","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.pan.2015.05.472_bib17","first-page":"158","article-title":"Combination of the deacetylase inhibitor panobinostat and the multi-kinase inhibitor sorafenib for the treatment of metastatic hepatocellular carcinoma - review of the underlying molecular mechanisms and first case report","volume":"3","author":"Gahr","year":"2012","journal-title":"J\u00a0Cancer"},{"issue":"4","key":"10.1016\/j.pan.2015.05.472_bib18","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.pan.2015.05.472_bib19","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1007\/s10620-012-2136-1","article-title":"Sorafenib for treatment of hepatocellular carcinoma: a systematic review","volume":"57","author":"Xie","year":"2012","journal-title":"Dig Dis Sci"},{"issue":"12","key":"10.1016\/j.pan.2015.05.472_bib20","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1358\/dot.2005.41.12.937959","article-title":"Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment","volume":"41","author":"Strumberg","year":"2005","journal-title":"Drugs Today (Barc)"},{"issue":"6","key":"10.1016\/j.pan.2015.05.472_bib21","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.jhep.2012.01.009","article-title":"Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib","volume":"56","author":"Lachenmayer","year":"2012","journal-title":"J\u00a0Hepatology"},{"issue":"156","key":"10.1016\/j.pan.2015.05.472_bib22","doi-asserted-by":"crossref","first-page":"156ra139","DOI":"10.1126\/scitranslmed.3004334","article-title":"A\u00a0preclinical evaluation of minnelide as a therapeutic agent against pancreatic cancer","volume":"4","author":"Chugh","year":"2012","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.1016\/j.pan.2015.05.472_bib23","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.surg.2014.04.055","article-title":"Sorafenib and triptolide as combination therapy for hepatocellular carcinoma","volume":"156","author":"Alsaied","year":"2014","journal-title":"Surgery"},{"issue":"2","key":"10.1016\/j.pan.2015.05.472_bib24","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1053\/j.gastro.2010.04.046","article-title":"Triptolide induces cell death in pancreatic cancer cells by apoptotic and autophagic pathways","volume":"139","author":"Mujumdar","year":"2010","journal-title":"Gastroenterology"}],"container-title":["Pancreatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1424390315005736?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1424390315005736?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T13:56:47Z","timestamp":1537538207000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1424390315005736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["S1424390315005736"],"URL":"https:\/\/doi.org\/10.1016\/j.pan.2015.05.472","relation":{},"ISSN":["1424-3903"],"issn-type":[{"value":"1424-3903","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Minnelide, a novel drug for pancreatic and liver cancer","name":"articletitle","label":"Article Title"},{"value":"Pancreatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pan.2015.05.472","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 IAP and EPC. Published by Elsevier, a division of Reed Elsevier India, Pvt. Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}